Boston Partners
MYGN icon

Boston Partners’s Myriad Genetics MYGN Stock Holding History

Boston Partners’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-37,838
Closed -$64.4K – 734
2022
Q4 		$64.4K Buy
+37,838
New +$705K ﹤0.01% 685
2013
Q3 		– Sell
-110,350
Closed -$2.96M – 714
2013
Q2 		$2.96M Buy
+110,350
New +$3.2M 0.01% 555

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Boston Partners's MYGN Position: Q1 2023 in Review

Boston Partners sold out of Myriad Genetics (MYGN) in Q1 2023, closing a stake of 37,838 shares — an estimated $64.4K sold.

Boston Partners first reported a position in MYGN in Q2 2013 and held it in 2 quarters. The position peaked at $2.96M in Q2 2013. 190 funds tracked by Wall St. Rank hold MYGN as of Q1 2023.

  • Boston Partners reported no remaining Myriad Genetics position as of Q1 2023 after selling out during the quarter.
  • Boston Partners sold 37,838 Myriad Genetics shares in Q1 2023, an estimated $64.4K.
  • Boston Partners first reported a position in Myriad Genetics in Q2 2013 and held it in 2 quarters.
  • Boston Partners's Myriad Genetics position peaked at $2.96M in Q2 2013.
  • 190 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2023.

Based on Boston Partners's 13F filing for Q1 2023, filed 9 May 2023.